Preclinical studies have demonstrated that stattic effectively inhibits STAT3 activity in various cancer cell lines, leading to reduced cell viability and increased apoptosis. These studies also showed that stattic could enhance the efficacy of other chemotherapeutic agents and radiation therapy, suggesting a potential for combination therapy. However, clinical trials are still needed to fully evaluate the safety and efficacy of stattic in human cancer patients.
